Table 3. List of patients who had maximum alanine aminotransferase ≥ 200 IU/L during angiotensin-II receptor blocker therapy with high probability of drug induced liver injury (RUCAM score ≥ 6).
| # | Age | Sex | ARB | Dose | Duration, days | Baseline ALT, IU/L | Peak ALT, IU/L | ASTa, IU/L | Albumina, g/dL | Bilirubina, mg/dL | ALPa, IU/L | GGTa, IU/L | Statin | Metformin | DM | Fatty liver | RUCAM | Department |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | 2 | Fimasartan | 30 | 88 | 35 | 383 | 324 | 4.7 | 1.3 | 97 | Y | Y | Y | N | 10 | IMC | |
| 2 | 64 | 1 | Fimasartan | 120 | 12 | 44 | 419 | 351 | 3.5 | 0.7 | 118 | Y | Y | Y | N | 10 | Others | |
| 3 | 72 | 2 | Fimasartan | 60 | 48 | 37 | 2,394 | 1,380 | 3.9 | 1.4 | 268 | 200 | Y | N | N | N | 10 | NR |
| 4 | 35 | 1 | Fimasartan | 60 | 146 | 39 | 218 | 110 | 4.7 | 0.9 | 75 | 33 | Y | N | N | Y | 9 | IMC |
| 5 | 47 | 1 | Fimasartan | 120 | 337 | 18 | 631 | 303 | 4.5 | 1.0 | 93 | 93 | Y | N | N | N | 9 | IMC |
| 6 | 49 | 2 | Fimasartan | 120 | 105 | 37 | 226 | 82 | 3.8 | 0.5 | 175 | 327 | Y | N | N | Y | 9 | IMN |
| 7 | 66 | 2 | Fimasartan | 60 | 91 | 41 | 300 | 211 | 3.2 | 1.0 | 64 | 204 | N | N | N | - | 8 | NR |
| 8 | 42 | 1 | Fimasartan | 30 | 212 | 59 | 260 | 105 | 4.7 | 1.5 | 49 | 58 | N | N | N | Y | 6 | IMC |
| 9 | 56 | 2 | Fimasartan | 30 | 105 | 19 | 840 | 434 | 3.2 | 0.7 | 118 | Y | N | N | N | 6 | IMN | |
| 10 | 59 | 1 | Fimasartan | 120 | 92 | 22 | 351 | 125 | 4.3 | 1.1 | 115 | Y | Y | Y | - | 6 | IMC | |
| 11 | 77 | 2 | Fimasartan | 120 | 196 | 12 | 241 | 267 | 3.8 | 0.5 | 68 | 43 | Y | N | N | N | 6 | IMN |
| 12 | 71 | 2 | Candesartan | 8 | 21 | 39 | 212 | 221 | 3.8 | 0.5 | 103 | Y | N | Y | N | 10 | IMC | |
| 13 | 59 | 2 | Candesartan | 8 | 241 | 24 | 220 | 159 | 3.9 | 0.8 | 57 | Y | N | N | N | 6 | IMC | |
| 14 | 58 | 1 | Candesartan | 16 | 298 | 6 | 629 | 299 | 4.0 | 0.9 | 310 | Y | N | Y | N | 6 | IMN | |
| 15 | 77 | 2 | Candesartan | 8 | 157 | 33 | 335 | 185 | 4.0 | 0.4 | 56 | Y | Y | Y | - | 6 | IMN | |
| 16 | 79 | 2 | Candesartan | 8 | 31 | 86 | 219 | 53 | 2.8 | 0.7 | 81 | 44 | Y | N | N | - | 6 | NS |
| 17 | 71 | 2 | Valsartan | 80 | 66 | 46 | 706 | 866 | 3.3 | 10.4 | 334 | 363 | Y | N | N | - | 6 | IMC |
| 18 | 66 | 1 | Valsartan | 80 | 861 | 24 | 1,570 | 1,480 | 3.3 | 14.1 | 268 | 114 | Y | N | N | - | 7 | IMC |
| 19 | 78 | 2 | Valsartan | 80 | 360 | 89 | 248 | 192 | 4.3 | 0.8 | 91 | 31 | N | N | Y | Y | 6 | IME |
| 20 | 60 | 2 | Valsartan | 80 | 55 | 12 | 206 | 117 | 4.5 | 0.4 | 60 | 12 | Y | Y | Y | - | 7 | IMC |
ARB = angiotensin-II receptor blocker, ALT = alanine aminotransferase, AST = aspartate aminotransferase, ALP = alkaline phosphatase, GGT = gamma-glutamyl transferase, DM = diabetes mellitus = RUCAM = Roussel Uclaf Causality Assessment Method, Y = yes, N = no, IMC = cardiology, NR = neurology, IMN = nephrology, NS = neurologic surgery, IME = endocrinology.
aData obtained the same date of maximum ALT.